Wednesday, November 25, 2015

Keeping Up With Rapid Advances in Hepatitis C Treatment

Keeping Up With Rapid Advances in Hepatitis C Treatment 

Pharmacy Practice News
ISSUE: NOVEMBER 2015 | VOLUME: 42

At the 2015 American College of Clinical Pharmacy’s Global Conference on Clinical Pharmacy, Linda Spooner, PharmD, BCPS (AQ-ID), FASHP, a professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences University, in Worcester, provided an overview of what pharmacists need to know.
Drug interaction assessments are critical, because some of the new medications won’t work when taken with certain drugs. For example, the fixed-dose combination ombitasvir-paritaprevir-ritonavir plus dasabuvir (Viekira Pak, AbbVie) is most susceptible to drug interactions with immunosuppressants and antiretroviral therapy, mainly due to the influence of ritonavir on multiple enzymes (Ann Pharmacother 2015;49[6]:674-687).

Read more...

No comments:

Post a Comment